Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337379 | 1.00 | GRM4 (0.47) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Hydrochloric Acid SCHEMBL31051190 | 0.98 | GRM4 (0.46) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Hydrochloric Acid SCHEMBL735826 | 0.98 | GRM4 (0.46) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Bromide SCHEMBL20984531 | 0.98 | GRM4 (0.46) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Hydrazine SCHEMBL6628605 | 0.96 | GRM4 (0.44) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Phosphoric Acid SCHEMBL20984832 | 0.90 | GRM4 (0.50) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Oxalic Acid SCHEMBL20984479 | 0.90 | GRM4 (0.50) | GRM4LMNAALDH1A1IDO1TDO2 | |
| Sulfuric Acid SCHEMBL20984645 | 0.90 | GRM4 (0.47) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| Nitric Acid SCHEMBL20984170 | 0.87 | GRM4 (0.45) | GRM4KCNH2LMNAALDH1A1IDO1 | |
| SCHEMBL2000165 | 0.84 | TUBB1 (0.46) | LMNAALDH1A1PIK3CARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210009523-A1 | Compounds and Compositions for the Treatment of Cancer | RASCAL THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3454862-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197036-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| CN-101516844-A | 4-heteroaryl substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having activity on opioid receptor systems | GRUENENTHAL GMBH (DE) | 2009-08-26 | — | — | CN | disclosed |
| EP-1328515-B1 | INDOLINE DERIVATIVES AND THEIR USE AS 5-HT2 RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| CN-1630636-A | Indoline derivatives and their use as 5-HT2 receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | GRM4 4218/4885KCNH2 4703/4885LMNA 2212/4885 |
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
| US-20210009523-A1 | Compounds and Compositions for the Treatment of Cancer | TP53, HCCS, CFTR | GRM4 4218/4885KCNH2 4703/4885LMNA 2212/4885 |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | GRM4 4218/4885KCNH2 4703/4885LMNA 2212/4885 |
| US-20190076540-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | GRM4 4038/4885KCNH2 4856/4885LMNA 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.